. Candida scores were determined entry into the study was to calculate the index of colonization option. Statistical analyzes This study is an exploratory study. The success rates as the number and percentage of patients per treatment with AB1010 Masitinib success at every moment Sented, with both sides exactly at 95% confidence intervals. Z two-sided tests were used to determine whether the proportions of treatment success differed significantly between patients with and without base were C. albicans, septic shock or Candid Chemistry, by reference APACHE II score or course of treatment, or by the rapid removal of the intravascular Ren catheter. survive after 90 days and the day of the first negative blood culture were based on Kaplan-Meier methods. Results The patients and treating a total of 221 patients were evaluated at 61 locations in 19 countries L.
The MITT and safety of Bev Lkerung comprised 216 and 170 patients. Baseline demographic and clinical characteristics of the MITT population Ren in Table 1 and Appen go To the 216 patients in the safety of Bev Lkerung were 151 newly combined U white Anidulafungin, 49 and 16 again U-withdrawal therapy with fluconazole or voriconazole, respectively. Treatment-related adverse events occurred in 33/216 patients who were at the h Ufigsten erythema, hypotension, increases hte alkaline phosphatase in the blood, increases hte aspartate aminotransferase, diarrhea, and atrial fibrillation. Most side effects were mild to moderate treatment related. In addition, only 1.9% of patients have severe side effects of treatment.
The type and H Were FREQUENCY of side effects in the general population and the safety for patients who again U anidulafungin only. Six patients AE as a potential infusion. Five patients were permanently set in the study because of Associated with the treatment AE. The 60 and 90 days survival Sch Estimates per day in the MITT population were 58.0% and 53.8% amount. Discussion This is the first prospective evaluation of therapy for C / IC specifically performed in patients in intensive care. This exploration was non-comparative clinical study best CONFIRMS the safety and efficacy of anidulafungin in the treatment of documented C / IC in some populations in adult intensive care patients, many patients with multiple comorbidities.
The success rate at EOT was high and the results were at this point in time usually Similar, independent Ngig from the ICU Bev Lkerung, pathogen, site of infection or clinical factors. Microbiological success rates were comparable to the respective global success. The incidence of side effects associated with treatment was low, indicating a very good compatibility Possibility of anidulafungin even in critically ill patients. Ver published Post-hoc analyzes of randomized clinical trials, success rates Similar or lower EOT have shown with fluconazole, amphotericin B, liposomal amphotericin B, caspofungin and micafungin in ICU patients with C / IC. A Similar post-hoc analysis showed a success rate of 69% with anidulafungin in patients in intensive care at EOIVT, compared with 76% of the total population Lkerung this study analyzes dealt only with non-response and unknown as treatment failures, w During our study excluded them from the prime Ren endpoint. If the F Ll were considered exemplary Lle was the success rate EOIVT world in our study are almost identical with the reported